Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 31.50 GBp
Change Today 0.00 / 0.00%
Volume 29.5K
FUM On Other Exchanges
As of 4:03 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

futura medical plc (FUM) Snapshot

31.50 GBp
Previous Close
31.50 GBp
Day High
31.50 GBp
Day Low
31.50 GBp
52 Week High
09/8/14 - 57.75 GBp
52 Week Low
01/21/15 - 26.25 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for FUTURA MEDICAL PLC (FUM)

Related News

No related news articles were found.

futura medical plc (FUM) Related Businessweek News

No Related Businessweek News Found

futura medical plc (FUM) Details

Futura Medical plc researches and develops pharmaceutical drugs and medical devices for the consumer healthcare market in the United Kingdom. The company offers CSD500, a condom that incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom; MED2002, a topical gel applied directly to the penis for the treatment of male erectile dysfunction; and PET500, a topical spray that enables men to prolong their sexual experience. Its pain relief management products, such as TPR100 and TIB200 incorporate a non-steroidal anti-inflammatory drug; and SPR300, a topical gel combines methyl salicylate and menthol. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

7 Employees
Last Reported Date: 03/25/15
Founded in 2001

futura medical plc (FUM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 237.7K GBP
Finance Director, Secretary, Financial Contro...
Total Annual Compensation: 142.1K GBP
Chief Scientific Officer and Adviser to the B...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

futura medical plc (FUM) Key Developments

Futura Medical Announces New Generation Topical Pain Relief Products

Futura Medical has developed a "new generation" of topical pain relief with two products that target more active ingredients directly to the point of pain. The new products have the potential to transform the pain relief market. Both products - TPR100 Diclofenac gel and TIB200 Ibuprofen gel - benefit from Futura's innovative multi-action skin permeation technology, DermaSys®, which offers deeper and more targeted pain relief for up to 12 hours. Earlier studies have shown up to twenty times greater drug penetration through the skin than existing brands. A recent in-vivo clinical trial strongly supported these findings, delivering statistically significant efficacy in pain relief.

Futura Medical plc Announces Headline Results from Pain Relief Portfolio Study

Futura Medical plc announced headline results from its clinical study of the company's portfolio of three topical pain relief products. The headline clinical data from the two non-steroidal anti-inflammatory (NSAID) products is very encouraging, with both products achieving all of their primary clinical endpoints. The data provides a clear pathway for the products' further development and reinforces the company's expectation of their commercial potential. The final study report is expected in September though preliminary analysis suggests there may be additional data to support marketing claims for the two NSAID products. Futura believes that certain trends observed may be indicative of the improved permeation of active compound through the dermis achieved by the company's DermaSys topical delivery system. The clinical study was of a randomised, double blind, crossover design in a model of induced pain. The skin of healthy volunteers was carefully exposed to a controlled amount of ultra-violet light to increase the sensitivity of the skin to pain stimuli. The effect of the three products was assessed over a six hour time period post dosing using two criteria: the primary pain measurement was the volunteers' sensation of pain (heat pain tolerance test) and the secondary pain measurement was the level of inflammation (as indicated by erythema, reddening of the skin). The 60 subjects were divided into three cohorts of 20. In the primary pain measurement, TPR100, whose active ingredient is the NSAID diclofenac, achieved statistically significant pain relief against placebo in both the 2% and 4% formulations. In addition, TIB200, whose active ingredient is ibuprofen, also achieved statistically significant pain relief against placebo. The methyl salicylate and menthol product, SPR300, did not meet its primary endpoint in the primary pain measurement. This clinical study was looking primarily at the anti-inflammatory properties of the compounds rather than its established counter-irritancy properties. Although the SPR300 arm of the study did not meet its primary endpoint, the robustness of this recent clinical study underlines Futura's commitment to developing compelling commercial products supported by evidence- based claims.

Futura Medical plc - Special Call

To discuss to announce the headline results from the clinical study of its portfolio of three topical pain relief products


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FUM:LN 31.50 GBp 0.00

FUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FUM.
View Industry Companies

Industry Analysis


Industry Average

Valuation FUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 705.6x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 702.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUTURA MEDICAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at